title: The inhibition of Wnt/β-catenin signaling pathway in human colon cancer cells by sulindac.
abstract: The aberrant activation of Wnt/β-catenin signaling plays important roles in the initial development of colon cancer. Sulindac is a commonly used non-steroidal anti-inflammatory drug. We demonstrated the effects of sulindac on growth inhibition, apoptosis induction, and Wnt/β-catenin signaling suppression in human colon cancer cells. Sulindac significantly inhibited proliferation of HT-29 colon cancer cells in a dose- and time-dependent manner. Sulindac was found to induce the apoptosis of HT-29 cells and inhibit the Wnt/β-catenin pathway. The inhibition was further confirmed by the decreased protein levels of β-catenin. The results indicate that sulindac may play a beneficial role in the comprehensive treatment of colon cancer.
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Tai
authors.forename: Pin-Jin
authors.initials: PJ
authors.lastname: Hu
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
authors.forename: Xiang-Chun
authors.initials: XC
authors.lastname: Lin
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D053148:Caspase 3; D049109:Cell Proliferation / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D003124:Colorimetry; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D019073:HT29 Cells; D006801:Humans; D015398:Signal Transduction / Q000187:drug effects*; D013467:Sulindac / Q000494:pharmacology*; D013997:Time Factors; D051153:Wnt Proteins / Q000187:drug effects / Q000378:metabolism*; D051176:beta Catenin / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; C495270:CTNNB1 protein, human; D051153:Wnt Proteins; D051176:beta Catenin; D013467:Sulindac; D053148:Caspase 3